NeoPharm, Inc. Announces PRECISE Trial Update

12/27/2005 01:07 PM

NeoPharm, Inc. (Nasdaq:NEOL) today announced that the independent Data Monitoring Committee ("DMC"), responsible for overseeing the Company's IL13-PE38QQR (cintredekin besudotox) Pivotal Phase III ...

 

NeoPharm Announces Completion of PRECISE Trial Enrollment as Per Special Protocol Assessment Agreement

12/09/2005 06:00 AM

NeoPharm, Inc. (Nasdaq:NEOL) today announced that it has received notification that the Company's cintredekin besudotox (IL13-PE38QQR) Pivotal Phase III PRECISE trial for the treatment of Glioblast...

 

NeoPharm to Present at First Albany Capital Annual Growth Conference

11/30/2005 06:00 AM

NeoPharm, Inc. (Nasdaq:NEOL) announced today that it has been invited to present at the First Albany Capital Annual Growth Conference scheduled for December 6-7, 2005.

 

NeoPharm Announces Precise Trial Update

11/21/2005 06:00 AM

NeoPharm (Nasdaq:NEOL) today announced that it has received notification that the Company's cintredekin besudotox (IL13-PE38QQR) Pivotal Phase III PRECISE trial for the treatment of Glioblastoma Mu...

 

NeoPharm Investigators Present Preliminary LErafAON-ETU Phase I Data at AACR-NCI-EORTC International Conference

11/15/2005 06:00 AM

NeoPharm, Inc. (Nasdaq:NEOL) today announced the presentation of preliminary Phase I results of the Company's NeoLipid(R) formulation of c-raf Antisense Oligonucleotide at the American Association ...

 

NeoPharm Announces September 30, 2005 Financial Results

11/01/2005 06:00 AM

NeoPharm, Inc. (Nasdaq:NEOL) today announced financial results for the third quarter and first nine months ended September 30, 2005.

 

NeoPharm Announces Appointment of Guillermo A. Herrera, Pharmaceutical Industry Executive, as President, Chief Executive Officer and Director

10/31/2005 06:00 AM

NeoPharm, Inc. (Nasdaq:NEOL) today announced that on October 28, 2005, its Board of Directors unanimously appointed Guillermo A. Herrera, 52, as the Company's President and Chief Executive Officer.

 

NeoPharm Sets Conference Call and Webcast for Third Quarter 2005 Corporate Results

10/18/2005 06:00 AM

NeoPharm, Inc. (Nasdaq:NEOL) today announced the date and time for its regularly-scheduled quarterly conference call to discuss corporate developments and financial highlights for the third quarter...

 

NeoPharm Investigators Present Preliminary Phase I Data of Cintredekin Besudotox in the Treatment of Malignant Glioma at Initial Diagnosis

10/10/2005 06:00 AM

NeoPharm, Inc. (Nasdaq:NEOL) today announced the presentation of initial safety data from a Phase I study of cintredekin besudotox in the treatment of newly diagnosed malignant glioma patients at t...

 

NeoPharm Announces Cintredekin Besudotox Poster Presentation at 55th Annual Meeting of the Congress of Neurological Surgeons (CNS)

10/04/2005 06:00 AM

 

NeoPharm Announces PRECISE Trial Update

10/03/2005 06:05 AM

 

NeoPharm Announces Shelf Registration Update; Shelf Registration Extended 3 Years Under New Securities Regulations

10/03/2005 06:00 AM

 

NeoPharm Announces LEP-ETU Project Update

09/29/2005 06:00 AM

 

NeoPharm, Inc. Updates Phase I/II Median Survival Data and PRECISE Trial

09/27/2005 06:00 AM

 

NeoPharm to Present at UBS 2005 Global Life Sciences Conference

09/20/2005 06:00 AM

 

NeoPharm Announces FDA Acceptance of Interim Efficacy Analysis Proposal for PRECISE Trial; -- Interim Efficacy Analysis to Occur at 160 Deaths

08/24/2005 06:00 AM

 

NeoPharm Announces Second Quarter and First Half 2005 Financial Results

07/29/2005 06:00 AM

 

NeoPharm Sets Conference Call and Webcast for Second Quarter 2005 Corporate Results

07/15/2005 06:00 AM

 

NeoPharm, Inc. Announces Precise Trial Update

06/27/2005 06:00 AM

 

NeoPharm Announces Delivery of Its First Customized NeoPhectin Formulation

06/23/2005 06:00 AM